Compounds > iqm 95333
Page last updated: 2024-11-10

iqm 95333

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5311188
CHEMBL ID113718
MeSH IDM0280828

Synonyms (6)

Synonym
iqm95333
CHEMBL113718 ,
iqm-95333
[(s)-1-((4as,5r)-2-benzyl-1,3-dioxo-octahydro-pyrido[1,2-c]pyrimidin-5-ylcarbamoyl)-2-(1h-indol-3-yl)-ethyl]-carbamic acid tert-butyl ester
bdbm50060319
tert-butyl n-[(2s)-1-[[(4as,5r)-2-benzyl-1,3-dioxo-4,4a,5,6,7,8-hexahydropyrido[1,2-c]pyrimidin-5-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]carbamate

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Oral administration of compounds 14a and 15a also produced a lasting antagonism to the hypomotility induced by CCK-8 in mice, suggesting a good bioavailability and metabolic stability."( 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
Ballaz, S; Bartolomé-Nebreda, JM; Cenarruzabeitia, E; Del Río, J; García-López, MT; Gómez-Monterrey, I; González-Muñiz, R; Herranz, R; LaTorre, M; Martín-Martínez, M, 1999)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cholecystokinin receptor type ARattus norvegicus (Norway rat)IC50 (µMol)0.00160.00000.43624.3000AID242786; AID52898; AID53034; AID53035
Cholecystokinin receptor type ARattus norvegicus (Norway rat)Ki2.89000.00010.27892.8900AID50506
Gastrin/cholecystokinin type B receptorRattus norvegicus (Norway rat)IC50 (µMol)10.00000.00010.24801.4000AID242785
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID182136Compound (CCK1 antagonist) was administered intraperitoneally for the effect of increase in plasma lipase activity induced by caerulein in rat at the dose of 1 mg/kg1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
AID195737Inhibition of amylase release stimulated by CCK-8 (0.1 nM) in dispersed pancreatic acini2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1)receptor antagonists: structure-activity relationship studies on the substituent at N2-position.
AID51445Inhibition of [3H]pCCK-8 specific binding to cholecystokinin type B receptor in rat cerebral cortex2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structure-activity relationship studies on the central 1,3-dioxoperhydropyrido[1,2-c]pyrimidine scaffold.
AID242786Inhibition of 71 pM [125I]BH-(Thr,Nle)CCK-9 binding to rat cholecystokinin 1 receptor2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor.
AID182130Compound (CCK1 antagonist) was administered orally for the effect of increase in plasma amylase activity induced by caerulein in rat at the dose of 0.1 mg/kg1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
AID182139Compound (CCK1 antagonist) was administered orally for the effect of increase in plasma lipase activity induced by caerulein in rat at the dose of 1 mg/kg1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
AID232488Selectivity as ratio of Ki against CCK-A and CCK-B receptors1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
AID51465Inhibition of [3H]- pCCK-8 binding to Cholecystokinin type B receptor of rat cerebral cortex membranes1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
AID242785Inhibition of 71 pM [125I]BH-(Thr,Nle)CCK-9 binding to rat cholecystokinin 2 receptor2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor.
AID181990Compound (CCK1 antagonist) was administered intraperitoneally for the effect of increase in plasma amylase activity induced by caerulein in rat at the dose of 1 mg/kg1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
AID182138Compound (CCK1 antagonist) was administered orally for the effect of increase in plasma lipase activity induced by caerulein in rat at the dose of 0.1 mg/kg1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
AID50506Inhibition of [3H]pCCK-8 specific binding to Cholecystokinin type A receptor of rat pancreas1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
AID179958Inhibition of amylase release stimulated by CCK-8 (0.1 nM) in dispersed rat pancreatic acini2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structure-activity relationship studies on the central 1,3-dioxoperhydropyrido[1,2-c]pyrimidine scaffold.
AID182131Compound (CCK1 antagonist) was administered orally for the effect of increase in plasma amylase activity induced by caerulein in rat at the dose of 1 mg/kg1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
AID52898Binding affinity by competitive inhibition of the radioligand [3H]pCCK-8 at Cholecystokinin type A receptor from rat pancreas1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
AID181989Compound (CCK1 antagonist) was administered intraperitoneally for the effect of increase in plasma amylase activity induced by caerulein in rat at the dose of 0.1 mg/kg1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
AID182135Compound (CCK1 antagonist) was administered intraperitoneally for the effect of increase in plasma lipase activity induced by caerulein in rat at the dose of 0.1 mg/kg1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
AID51440Binding affinity by competitive inhibition of the radioligand [3H]pCCK-8 at Cholecystokinin type B receptor from rat cerebral cortex membrane1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
AID53035Inhibition of [3H]pCCK-8 binding to cholecystokinin type A receptor of rat pancreas2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structure-activity relationship studies on the central 1,3-dioxoperhydropyrido[1,2-c]pyrimidine scaffold.
AID53034Inhibition of [3H]pCCK-8 specific binding to cholecystokinin type A receptor in rat pancreas2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1)receptor antagonists: structure-activity relationship studies on the substituent at N2-position.
AID51444Inhibition of [3H]pCCK-8 specific binding cholecystokinin type B receptor in rat cerebral cortex membranes2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1)receptor antagonists: structure-activity relationship studies on the substituent at N2-position.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's3 (60.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
devazepide
Devazepide: A derivative of benzodiazepine that acts on the cholecystokinin A (CCKA) receptor to antagonize CCK-8's (SINCALIDE) physiological and behavioral effects, such as pancreatic stimulation and inhibition of feeding.. devazepide : An indolecarboxamide obtained by formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. A cholecystokinin antagonist used for treatment of gastrointestinal disorders.		2101,4-benzodiazepinone;
indolecarboxamide		antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug
sincalide
Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.		2.6930oligopeptide
ConditionIndicatedRelationship StrengthStudiesTrials
Hyperactivity, Motor
[description not available]		0210
Acute Edematous Pancreatitis
[description not available]		0210
Acute Disease
Disease having a short and relatively severe course.		0210
Pancreatitis
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.		0210